The Emergence of COVID-19 to Augment the DNA Sequencing Equipment and Services Market Growth
Next generation sequencing is any of several high-throughput methods to DNA sequencing using the concept of massively parallel processing. DNA sequencing equipment is widely used to determine the precise order of nucleotide within a DNA molecule. The equipment reports the text string in terms of the four bases namely thymine (T), adenine (A), cytosine (C), and guanine (G). DNA sequencing equipment is also capable of analyzing the light signals, which are originated from fluorochromes attached to nucleotides.
Market Dynamics:
Favorable government initiatives
to support for large-scale sequencing, advancements in next-generation
sequencing (NGS) platforms, and rapid advancements in sequencing technology and
bioinformatics are expected to augment the growth of the DNA sequencing equipment and services market. For instance, in 2020, Helix OpCo received Emergency
Use Authorization (EUA) from the Food and Drug Administration (FDA) for its
Helix COVID-19 NGS Test for the detection of the infection.
The outbreak of COVID-19 (SARS-CoV-2) has offered many
growth opportunities to market players, as well as many government and
non-government organizations. For instance, in June 2020, Illumina received EUA
for its COVIDSeq Test that is used to sequence the full genome of the virus.
Moreover, in May 2020, Genetics of Mortality in Critical Care, Genomics
England, and the National Health Service of U.K. teamed up with Illumina to
generate whole-genome sequences of around 35,000 COVID-19 citizens in the U.K.
Furthermore, strategic initiatives undertaken by market
players, to expand their presence, are expected to propel the growth of the DNA
sequencing equipment and services market. For instance, in 2020, GenapSys raised
around US$ 75 million to bring its tabletop DNA sequencer to Asia amid
coronavirus outbreak.
Competitive Analysis:
Major players operating in the DNA sequencing equipment and
services market are Agilent Technologies, ZS Genetics, Thermo Fisher Scientific
Inc., Siemens AG, Pacific Biosciences, Microchip Biotechnologies, Johnson &
Johnson, Hamilton Thorne Biosciences, GE Healthcare Life Sciences, Commonwealth
Biotechnologies, Beckman Coulter, Bayer Corporation, and Abbott Laboratories.
Major players in the market are adopting various inorganic
strategies, such as merger and collaboration, to strengthen their market position.
For instance, in March 20221, RevoluGen, under its collaboration agreement with
Tecan, announces the technology validation (by DNA sequencing) of the world’s
first automated extraction of library-ready High Molecular Weight (HMW) DNA in
a multi-well filter plate format.
In February 2021, SoftBank Group Corp announced to invest US$
900 million into Pacific Biosciences to strengthen Pacific’s position in the
long-read DNA sequencing market.
Comments
Post a Comment